Clinical and epidemiological characteristics and risk factors for the development of recurrent respiratory diseases in children
Abstract
OBJECTIVE: Aim: To investigate the influence of risk factors on the development of recurrent respiratory diseases, to analyze clinical and epidemiological components for the possibility of their prevention. PATIENTS AND METHODS: Materials and Methods: The research was conducted on the basis of the Uzhhorod Children Primary School. Children studied groups (n=118) aged 6-9 years with a diagnosis of "acute recurrent respiratory diseases" were formed. RESULTS: Results: Childrens inflammatory episodes were most often observed, in particular: bacterial tonsillitis - 86 (72,89%), otitis - 56 (47,46%), pneumonia and sinusitis - 37 (31,36%) (identical indicators). In our study, respiratory infection caused by at least one pathogen was observed in 63,4±4,1% of patients. The proportion of viral infections was 48,34±3,6%, in particular, coinfections were identified in 36,4±2,9% of cases. The distribution of confirmed viruses is as follows: AdV (26,34±1,7%), SARS-CoV-2 (19,5±1,6%), RV (18,2%), RSV (17,8%), influenza A/B (11,4%) and others in minimal structural components (6.8%). CONCLUSION: Conclusions: Recurrent respiratory tract infection is a multifactorial disease caused by a complex interaction of environmental and host factors. We suggest that an "additive effect," depending on the number of factors involved, most of which may be underestimated, may be a plausible explanation for the recurrence of respiratory tract infection in a significant proportion of healthy children with…
Read the paper
Related studies
- Impact of antibiotics on the human microbiome and consequences for host health
- Antibiotics in the clinical pipeline in October 2019
- The incidence of collagen-associated adverse events in pediatric population with the use of fluoroquinolones: a nationwide cohort study in Taiwan
- Research Communications of the 32nd ECVIM-CA Online Congress
- Singlet-Oxygen Therapy. Scientific And Methodological Materials
- Artificial Intelligence in Pharmacovigilance
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.